Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 4/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960973 | 0.84 | — | — | |
| SCHEMBL24960909 | 0.78 | CTSL (0.52) | CTSLCTSS | |
| SCHEMBL24960911 | 0.75 | CTSL (0.60) | CTSLCTSS | |
| SCHEMBL24960976 | 0.74 | — | — | |
| SCHEMBL24960974 | 0.74 | CTSL (0.62) | CTSLCTSS | |
| SCHEMBL26224037 | 0.72 | F2R (0.49) | — | |
| SCHEMBL24960912 | 0.72 | F2R (0.49) | — | |
| SCHEMBL24961120 | 0.72 | F2R (0.52) | CCKBRCYP51A1CTSS | |
| SCHEMBL24960419 | 0.71 | — | — | |
| SCHEMBL25861546 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | DRD2 4624/4885CCKBR 1799/4885CYP51A1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.